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Abstract
The dietary inﬂammatory index (DIITM) is a novel composite score based on a range of nutrients and foods known to be associated with
inﬂammation. DII scores have been linked to the risk of a number of cancers, including oesophageal squamous cell cancer and oesophageal
adenocarcinoma (OAC). Given that OAC stems from acid reﬂux and that the oesophageal epithelium undergoes a metaplasia-dysplasia
transition from the resulting inﬂammation, it is plausible that a high DII score (indicating a pro-inﬂammatory diet) may exacerbate risk of OAC
and its precursor conditions. The aim of this analytical study was to explore the association between energy-adjusted dietary inﬂammatory
index (E-DIITM) in relation to risk of reﬂux oesophagitis, Barrett’s oesophagus and OAC. Between 2002 and 2005, reﬂux oesophagitis (n 219),
Barrett’s oesophagus (n 220) and OAC (n 224) patients, and population-based controls (n 256), were recruited to the Factors inﬂuencing the
Barrett’s Adenocarcinoma Relationship study in Northern Ireland and the Republic of Ireland. E-DII scores were derived from a 101-item FFQ.
Unconditional logistic regression analysis was applied to determine odds of oesophageal lesions according to E-DII intakes, adjusting for
potential confounders. High E-DII scores were associated with borderline increase in odds of reﬂux oesophagitis (OR 1·87; 95% CI 0·93, 3·73),
and signiﬁcantly increased odds of Barrett’s oesophagus (OR 2·05; 95% CI 1·22, 3·47), and OAC (OR 2·29; 95% CI 1·32, 3·96), when comparing
the highest with the lowest tertiles of E-DII scores. In conclusion, a pro-inﬂammatory diet may exacerbate the risk of the inﬂammation-
metaplasia-adenocarcinoma pathway in oesophageal carcinogenesis.
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Oesophageal cancer is the eighth most common cancer and
sixth most common cause of cancer-related death worldwide,
with 456 000 new oesophageal cancer cases and 400 000 deaths
in 2012(1). Oesophageal adenocarcinoma (OAC) arises from
glandular cells of the lower third of the oesophagus, whereas
squamous cell carcinoma of the oesophagus originates from the
epithelial cells. The incidence of OAC has risen at an alarming
rate in Western populations since the early 1970s; however,
rates of oesophageal squamous cell carcinoma, which were
much higher relative to adenocarcinomas decades ago, have
remained steady for many decades(2,3). Barrett’s oesophagus
(BE), a condition of the distal oesophagus wherein the stratiﬁed
squamous epithelium is replaced by columnar intestinal
epithelium, is a recognised precursor of adenocarcinoma(3).
There is also growing evidence linking chronic inﬂammation to
OAC(4,5). Major risk factors for this cancer and its precursor
conditions include cigarette smoking and obesity(6); whereas,
there is consistent evidence showing that frequent use of
non-steroidal anti-inﬂammatory drugs lowers risk of OAC(7,8).
Several studies have been conducted exploring the association
between dietary factors and OAC and BE, with strong epide-
miological evidence for an inverse relationship between intake
of vitamin C, β-carotene, dietary ﬁbre, fruits and vegetables and
the risk of OAC and BE(9,10).
The dietary inﬂammatory index (DIITM) was developed to
assess the inﬂammatory potential of an individual’s diet(11).
A pro-inﬂammatory diet is characterised by a high consumption
of foods rich in SFA and carbohydrates, and a low consumption
Abbreviations: BE, Barrett’s oesophagus; DII, dietary inﬂammatory index; E-DII, energy-adjusted dietary inﬂammatory index; OAC, oesophageal
adenocarcinoma; RE, reﬂux esophagitis.
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of foods rich in ﬁbre, PUFA, ﬂavonoids and other antioxidant
dietary components. The DII has been validated in a variety of
longitudinal and cross-sectional studies with various inﬂamma-
tory markers, including C-reactive protein (CRP)(12), IL-6(13) and
TNF-α(14). The DII has been associated with risk of colorectal
cancer in case–control studies in Spain and Italy(15,16); in
three cohort studies from the USA(17–19), and risk of pancreatic,
prostate, hepatocellular and oesophageal squamous cell cancers
in case–control studies in Italy(20–23). Only one previous study,
conducted in Sweden, has investigated the association between
DII and OAC; it demonstrated 4-fold increased odds of OAC
amongst those consuming the most inﬂammatory diets(24).
To our knowledge, no previous study has investigated the
relationship between DII scores and pre-malignant conditions of
the oesophagus. The aim of this investigation was to evaluate the
association between DII and risk of reﬂux esophagitis (RE), BE
and OAC in an all-Ireland population-based case–control study.
Methods
Study design
Participants of the all-Ireland Factors inﬂuencing the Barrett’s
Adenocarcinoma Relationship (FINBAR) study(25–27) were
utilised for this analysis. The FINBAR study recruited four
participant groups: (i) patients with incident, histologically con-
ﬁrmed, OAC (n 227), (ii) patients with long-segment BE, deﬁned
as >3 cm of non-dysplastic specialised intestinal metaplasia
(n 224), (iii) patients with RE (n 230), deﬁned as having
oesophageal erosions scored as grades 2–4 on the Savary-Miller/
Hetzel-Dent scale or grades B, C or D on the Los Angeles
scale(28) and (iv) population-based controls (n 260) with no
previous history of BE, oesophageal or other gastrointestinal
cancer. Population controls, RE and BE patients were frequency
matched by sex and 5-year age strata to OAC patients following
recruitment of OAC patients(25–27).
Recruitment has been described in detail in previous publica-
tions(25–27). In brief, patients with oesophageal lesions were
identiﬁed from electronic pathology records in Northern Ireland
and hospital clinical records in Dublin and Cork in the Republic of
Ireland. Eligible control subjects were adults without a history
of oesophageal or other gastrointestinal cancer or a known
diagnosis of BE. Northern Ireland controls were selected at
random from the General Practice Master Index (a province-wide
database of all persons registered with a general practitioner).
Republic of Ireland controls were selected at random from four
general practices (two urban and two rural) in the Dublin and
Cork areas chosen by the researchers. Study participants were
recruited between March 2002 and July 2004, with the exception
of RE patients, who were recruited in Northern Ireland only
between 2004 and 2005. This study was conducted according to
the guidelines laid down in the Declaration of Helsinki and
all procedures involving human subjects were approved by the
Research Ethics Committees of Queen’s University Belfast,
Northern Ireland, Clinical Research Ethics Committee of Cork
Teaching Hospitals and Research Ethics Committee Board of
St. James’s Hospital, Dublin. Written informed consent was
provided by all FINBAR study participants.
Data collection
Trained interviewers collected information on demographics,
lifestyle, medication and co-morbidities from study participants
using a standardised electronic questionnaire. Participants were
asked to self-report their weight 5 years before interview in
order to calculate BMI at that time, by dividing self-reported
weight (kg) by current height (m2), as measured by the
interviewer. Serum samples were taken and Helicobacter
pylori infection status assessed using a Western blot assay, as
previously described(29).
Dietary assessment and dietary inﬂammatory index
calculation
Dietary intake was assessed using a 101-item FFQ. Participants
were asked to recall their dietary habits 5 years before interview
when completing the FFQ, to minimise the impact of disease on
changes in dietary intakes. The FFQ was adapted for the Irish
population from the European Prospective Investigation into
Cancer and Nutrition study FFQ(30), by incorporating additional
foods reported as commonly eaten in the Northern/Southern
Ireland Food Consumption Survey(31). Mean daily nutrient and
food intakes were calculated from the FFQ using Q-Builder
(Tinuviel Software).
In order to compute the DII score, dietary information for each
study participant is ﬁrst linked to the regionally representative
database that provided a global estimate of mean intake for each
of the forty-ﬁve parameters (i.e. foods, nutrients and other food
components) along with its standard deviation considered in the
DII deﬁnition(11). These parameters then are used to derive the
participant’s exposure relative to the standard global mean as
a z-score, derived by subtracting the mean of the regionally
representative database from the amount reported, and dividing
this value by the parameter’s standard deviation. These z-scores
are converted to percentiles (expressed as a proportion; i.e. with
values ranging from 0 to 1) and then centring by doubling and
subtracting 1. Clinical interpretation remains clear with these
additional steps and inappropriate weighting is avoided and
higher (i.e. more positive) DII scores invariably represent more
pro-inﬂammatory diets. The resulting value is then multiplied by
the corresponding food parameter effect score (derived from a
literature review on the basis of 1943 articles(11)).
All of these food parameter-speciﬁc DII scores are then sum-
med to create the overall DII score for every subject in the study.
To control for the potential confounding effect of total energy
intake, the energy-adjusted dietary inﬂammatory index (E-DII)
was calculated per 1000kcal (equivalent to 4180 kJ) energy
content of food consumed wherein all the food parameters were
divided by energy intake and multiplied by 1000 kcal (equivalent
to 4180 kJ). A total of twenty-ﬁve of the forty-ﬁve possible food
parameters were used for DII calculation based on the FFQ in
this study and these were as follows: energy, carbohydrate,
protein, fat, alcohol, ﬁbre, cholesterol, SFA, MUFA, PUFA, niacin,
thiamin, riboﬂavin, vitamin B12, vitamin B6, Fe, Mg, Zn, Se,
vitamin A, vitamin C, vitamin D, vitamin E, folic acid and
β-carotene. The missing food parameters were anthocyanidins,
ﬂavonols, ﬂavan-3-ol, ﬂavonones, isoﬂavanoids, ﬂavones,
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eugenol, caffeine, tea, garlic, ginger, onion, saffron, turmeric,
pepper, thyme/oregano, rosemary, n-3, n-6 and trans-fat. Energy
was not included as the DII is already adjusted for it. Fig. 1
describes the steps involved in DII calculation.
Statistical analysis
Participants were excluded from the analysis if they failed to
complete the FFQ (n 22). A total of 256 controls, 219 RE, 220 BE
and 224 OAC cases were available in the analytical data set.
All statistical analysis was performed using Intercooled Stata®
version 11.0 (StataCorp LP).
Characteristics were compared between patient groups and
controls using independent t tests for continuous variables and
χ2 tests for categorical variables. RE analyses were restricted to
Northern Ireland controls only, because these patients were
recruited in Northern Ireland only. Tertiles of E-DII intakes
were deﬁned by distribution in the appropriate controls.
Unconditional logistic regression analysis was applied to
generate OR and corresponding 95% CI for oesophageal
lesions according to tertiles of E-DII. In order to test for trend,
each individual was assigned the median intake value for the
tertile into which they were classiﬁed, and this was included in
the regression model as a continuous variable.
Known confounders for oesophageal lesions within this
study population(25,26,29,32–35) were included in the regression
models. These included log energy intake (log kJ/d (kcal/d)),
age (years) and sex for model 1, and added smoking status
(current/previous/never), education (years), BMI 5 years before
interview (kg/m2), occupation (manual/non-manual), alcohol
intake (g/d), regular non-steroidal inﬂammatory drug use
(weekly use for at least 6 months duration), H. pylori infection
(seronegative/seropositive) and geographical location
(Northern Ireland/Republic of Ireland) in model 2. In a third
model, we further tested for regular gastro-oesophageal reﬂux
symptoms (ever/never), because it is debatable whether reﬂux
symptoms may confound or be on the causal pathway between
oesophageal lesion risk and DII intake. To investigate this
further, we also conducted stratiﬁed analysis by reported
experience of gastro-oesophageal reﬂux symptoms. Stratiﬁed
analysis by H. pylori infection status, BMI and smoking status
also were conducted, as these confounders most signiﬁcantly
inﬂuenced the association between E-DII and oesophageal
lesion risk in regression models.
Results
As shown in Table 1, OAC patients were more likely to be
smokers, consume less alcohol and have higher energy intake,
have a higher BMI, have worked in manual occupations and
completed fewer years of education and were less likely to have
a history of H. pylori infection compared with controls. Similar
trends were observed for BE and RE patients compared with
controls, although these differences were not always statistically
signiﬁcant. All three patient groups were more likely to have
experienced gastro-oesophageal reﬂux symptoms and consume
higher E-DII diets compared with controls. The range of E-DII
scores was −3·08 to +4·74.
The association between E-DII scores and disease risk is
shown in Table 2. Strong dose–response associations were
observed for E-DII and odds of all three diseases in models
adjusted for age, sex and energy intakes. When known
confounders were added into the model, E-DII was no longer
signiﬁcantly associated with RE (OR 1·87; 95% CI 0·93, 3·73).
When comparing high v. low tertiles of E-DII, signiﬁcantly
increased odds of BE and OAC remained following further
adjustment for additional confounders (OR 2·05; 95% CI 1·22,
3·47 and OR 2·29; 95% CI 1·32, 3·96, respectively).
In exploratory analysis with further adjustment for gastro-
oesophageal reﬂux symptoms, the general direction of associa-
tions remained but statistical signiﬁcance became attenuated,
suggesting there may be an interaction between reﬂux symptoms,
E-DII and risk of oesophageal lesions (Table 2). Stratiﬁed analysis
by reﬂux symptoms indicated relatively consistent increased
odds of RE and BE for individuals consuming a high E-DII diet
regardless of symptom experience, although statistical power
was limited and again statistical signiﬁcance was lost (Table 3).
However, a stronger positive association between high E-DII score
and odds of OAC was observed for individuals who reported
experiencing regular gastro-oesophageal reﬂux symptoms
(T3 v. T1: OR 2·76; 95% CI 0·99, 7·71) compared with those not
reporting regular symptoms (T3 v. T1: OR 1·73; 95% CI 0·87, 3·45),
although the interaction test was not signiﬁcant (P= 0·34)
In analysis stratiﬁed by H. pylori infection status (Table 4), we
observed stronger positive associations between high E-DII
intakes and odds of RE, BE, but not OAC, in H. pylori positive
individuals compared with H. pylori negative individuals.
However, formal tests for statistical interaction were not
signiﬁcant.
No clear patterns emerged in stratiﬁed analysis of E-DII and
oesophageal lesion risk by smoking status or BMI (online
Supplementary Tables S1 and S2). Again, statistical tests for
interaction between E-DII and smoking or BMI in relation to
disease risk were not signiﬁcant.
Discussion
In this all-Ireland population-based study, a pro-inﬂammatory
diet, as evidenced by high E-DII scores, was associated with
increased odds of RE, BE and OAC, with statistically signiﬁcant
associations being observed for the latter two conditions. These
results are in line with the only previous study to explore DII and
OAC, where increasing inﬂammatory potential of diet was also
associated with increased odds of OAC (OR Quartile 4 v. 1: 3·59;
95% CI 1·87, 6·89)(24). To our knowledge, this is the ﬁrst study to
have examined the association between DII and BE and RE.
Previously, results from this case–control study have
demonstrated that folate intake was associated with reduced
risk of OAC whereas vitamin B6 intake was associated with
reduced risk of OAC, BE and RE and vitamin B12 was associated
with increased risk of OAC(36) and dietary Mg intakes were
inversely associated with RE and BE(37). In the context of the
DII; folate, vitamins B6, and Mg have anti-inﬂammatory effect
scores whereas vitamin B12 has a pro-inﬂammatory effect
score(11), therefore our results are biologically plausible and
consistent with previous ﬁndings.
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20 food parameters were not included
for this study.* Energy was not included
as the E-DII is already adjusted for it
The score for each food parameter was weighted according to the study design. The weights were
10 (experimental design), 8 (observational), 7(case–control), 6 (cross-sectional), 5 (experimental
with animals), 3 (cell culture)
A score for each food parameter was calculated giving:
+1 to each article if the effects were pro-inflammatory (significantly increased IL-1, IL-6, TNF- or
CRP, or decreased IL-4 or IL-10), 
–1 if the effects were anti-inflammatory (significantly decreased IL-1, IL-6, TNF- or CRP, or
increased IL-4 or IL-10),
0 if the food parameter did not produce any significant change in the inflammatory marker
A food parameter-specific overall inflammatory effect score was calculated by substracting the
anti-inflammatory fraction from the pro-inflammatory fraction. This score was corrected if the
total weighted number of articles was <236. In these cases the raw overall inflammatory score was
multiplied by the total weighted number of articles divided by 236
z-score and centred-percentiles for each of the 24 available food parameters for each participant
were calculated based on the average and standard deviation for each food parameter obtained
from the global database which was created from the consumption of the original 45 food 
parameters from 11 countries
The centred percentile for each food parameter was multiplied by the respective ‘overall food
parameter-specific inflammatory effect score’ to obtain the ‘food parameter-specific DII score’
All of the ‘food parameter-specific DII scores’ were summed to create the ‘overall DII score’ for
each individual
Review of articles published from 1950 to 2010 resulting in 1943 studies linking a total of 45 food
parameters with inflammatory biomarkers
Fig. 1. Sequence of steps in creating the dietary inflammatory index in the Factors influencing the Barrett’s Adenocarcinoma Relationship study. CRP, C-reactive
protein; E-DII, energy-adjusted dietary inflammatory index; DII, dietary inflammatory index. *Missing food items were anthocyanidins, flavonols, flavan3ol, flavonones,
isoflavanoids, flavones, eugenol, caffeine, tea, garlic, ginger, onion, saffron, turmeric, pepper, thyme/oregano, rosemary, n-3, n-6 and trans-fat.
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Table 1. Characteristics of reflux oesophagitis, Barrett’s oesophagus and oesophageal adenocarcinoma cases and controls, Factors influencing the Barrett’s Adenocarcinoma Relationship study
(Numbers and percentages; mean values and standard deviations)
Northern Ireland controls
(n 119)
Reflux oesophagitis
(n 219)
All controls
(n 256)
Barrett’s oesophagus
(n 220)
Oesophageal adenocarcinoma
(n 224)
Characteristics n % n % P* n % n % P† n % P†
Age (years) 68·1 10·3 61·9 11·5 <0·001 63·0 12·9 62·3 12·0 0·50 64·3 11·2 0·25
Males 83 69·8 183 83·6 0·003 216 84·4 181 82·3 0·54 189 84·4 1·00
Location
Northern Ireland 119 100 219 100 – 119 46·5 150 68·2 <0·001 114 50·9 0·34
Republic of Ireland 0 0 0 0 137 53·5 70 31·8 110 49·1
Smoking status
Never 51 43·6 106 49·5 0·27 100 40·2 87 39·7 0·33 45 20·6 <0·001
Previous 44 37·6 62 29·0 105 42·2 82 37·4 98 44·8
Current 22 18·8 46 21·5 44 17·7 50 22·8 76 34·7
Occupation type
Manual 54 47·0 106 49·5 0·66 123 49·4 127 58·5 0·05 131 60·1 0·02
Non-manual 61 53·0 108 50·5 126 50·6 90 41·5 87 39·9
Regular GOR symptoms‡ 28 23·5 87 39·7 0·003 49 19·2 159 72·3 <0·001 108 48·2 <0·001
Regular NSAID use§ 15 12·8 38 17·4 0·27 31 12·2 29 13·2 0·75 23 10·3 0·52
Helicobacter·pylori positive 76 65·0 92 42·4 <0·001 145 58·5 106 50·5 0·09 102 49·0 0·04
Mean SD Mean SD Mean SD Mean SD Mean SD
Education (years) 11·1 2·6 10·7 2·1 0·15 12·0 3·2 11·3 2·9 0·02 10·7 2·6 <0·001
BMI 5 years before interview (kg/m2) 27·2 4·1 27·7 4·5 0·25 27·1 3·9 26·9 4·0 0·74 28·6 4·9 0·001
Alcohol intake (g/d) 13·2 0·7 16·3 20·8 0·20 19·2 23·1 16·5 23·9 0·21 14·1 20·6 0·01
Energy (kJ/d) 10 828 3736 11 263 3125 10 777 3393 11385 3222 11 531 3402 0·02
Energy (kcal/d) 2588 893 2692 747 0·26 2576 811 2721 770 0·05 2756 813
E-DII (DII/4184 kJ/d (1000 kcal/d)) 0·8 1·7 1·6 1·5 <0·001 1·1 1·6 1·6 1·6 <0·001 1·7 1·7 <0·001
GOR, gastro-oesophageal reflux; NSAID, non-steroidal anti-inflammatory drug; E-DII, energy-adjusted dietary inflammatory index; DII, dietary inflammatory index.
* Cases compared with Northern Ireland controls only, calculated using the t test (continuous variables) or χ2 test (categorical variables).
† Cases compared with all controls, calculated using the t test (continuous variables) or χ2 test (categorical variables).
‡ Heartburn/acid reflux symptoms experienced at least once weekly or >50 times/year >5years before interview date.
§ Ever use defined as use at least once weekly for ≥6 months duration.
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Results from other studies exploring dietary components that
contribute to the DII score and OAC have been largely in line
with the diet-associated inﬂammation hypothesis. For example,
reports from a meta-analyses on eight studies showed an
inverse association between dietary ﬁbre intake and OAC(10).
In another meta-analysis, increased ﬁsh intake was associated
with reduced risk(38). Dietary ﬁbre and n-3 in ﬁsh have anti-
inﬂammatory DII scores(11).
Table 3. Dietary inflammatory index density and risk of reflux oesophagitis, Barrett’s oesophagus and oesophageal adenocarcinoma, stratified by gastro-
oesophageal reflux symptom experience, Factors influencing the Barrett’s Adenocarcinoma Relationship study
(Odds ratios and 95% confidence intervals)
No regular reflux symptoms Regular reflux symptoms
Adjusted* Adjusted*
Controls/cases OR 95% CI Controls/cases OR 95% CI Pfor interaction
Reflux oesophagitis†
E-DII
<−0·12 33/20 1·00 6/14 1·00
− 0·12–<1·91 31/49 1·55 0·68, 3·55 9/33 1·67 0·36, 7·66
≥1·91 27/63 2·33 1·00, 5·46 13/40 0·83 0·20, 3·48
Pfor trend 0·05 0·70 0·32
Barrett’s oesophagus
E-DII
<0·34 72/14 1·00 13/31 1·00
0·34−<1·98 72/21 1·56 0·68, 3·57 14/55 1·85 0·71, 4·80
≥1·98 62/26 2·05 0·89, 4·76 22/73 1·69 0·68, 4·21
Pfor trend 0·09 0·31 0·97
Oesophageal adenocarcinoma
E-DII
<0·34 72/28 1·00 13/17 1·00
0·34−<1·98 72/34 1·08 0·53, 2·17 14/37 2·81 0·94, 8·42
≥1·98 62/54 1·73 0·87, 3·45 22/54 2·76 0·99, 7·71
Pfor trend 0·10 0·08 0·34
DII, dietary inflammatory index.
* Adjusted for age (years), sex, energy intake, smoking status (current/previous/never), BMI 5 years before interview, education (years), occupation (manual/non-manual), alcohol
(g/d), regular non-steroidal inflammatory drug use (ever/never), Helicobacter pylori infection (seropositive/seronegative) and location (Northern Ireland/Republic of Ireland).
† Analysis limited to Northern Ireland controls only.
Table 2. Dietary inflammatory index density and risk of reflux oesophagitis, Barrett’s oesophagus and oesophageal adenocarcinoma, Factors influencing
the Barrett’s Adenocarcinoma Relationship study
(Odds ratios and 95% confidence intervals)
Model 1* Model 2† Model 3‡
Controls (n) Cases (n) OR 95% CI OR 95% CI OR 95% CI
Reflux oesophagitis§ 119 219
E-DII
<−0·12 39 34 1·00 1·00 1·00
−0·12–<1·91 40 82 1·74 0·93, 3·27 1·43 0·72, 2·84 1·41 0·71, 2·82
≥1·91 40 103 2·14 1·15, 3·98 1·87 0·93, 3·73 1·82 0·90, 3·67
Pfor trend 0·02 0·08 0·09
Barrett’s oesophagus 256 220
E-DII
<0·34 85 45 1·00 1·00 1·00
0·34–<1·98 86 76 1·71 1·06, 2·77 1·75 1·04, 2·95 1·60 0·87, 2·93
≥1·98 85 99 2·30 1·43, 3·71 2·05 1·22, 3·47 1·75 0·95, 3·20
Pfor trend 0·001 0·008 0·08
Oesophageal adenocarcinoma 256 224
E-DII
<0·34 85 45 1·00 1·00 1·00
0·34–<1·98 86 71 1·67 1·03, 2·73 1·61 0·92, 2·82 1·44 0·81, 2·57
≥1·98 85 108 2·59 1·61, 4·14 2·29 1·32, 3·96 1·96 1·11, 3·47
Pfor trend <0·001 0·003 0·02
DII, dietary inflammatory index.
* Model 1: adjusted for age (years), sex and energy intake.
† Model 2: adjusted for model 1 + smoking status (current/previous/never), BMI 5 years before interview, education (years), occupation (manual/non-manual), alcohol (g/d), regular
non-steroidal inflammatory drug use (ever/never), Helicobacter pylori infection (seropositive/seronegative) and location (Northern Ireland/Republic of Ireland).
‡ Model 3: adjusted for model 2 + regular gastro-oesophageal reflux symptoms (ever/never).
§ Analysis limited to Northern Ireland controls only.
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The results from this study showing a positive association
between a pro-inﬂammatory diet and OAC, BE and RE can be
considered promising for diet-based prevention or chemopre-
vention of these conditions. Phytochemicals in the diet have been
shown to increase necrosis and apoptosis in Barrett’s cells
through inhibiting the inﬂammatory reaction, and to exhibit a
similar effect on OAC cells(39). Resveratrol, which is present
in relatively large quantities in grapes, was found to be a
natural COX-2 inhibitor that is involved in the anti-inﬂammatory
pathway(40). Another phytochemical, curcumin, which can
down-regulate inﬂammation, was demonstrated to be capable of
abolishing the ability of deoxycholic acid to activate NF-κB(41).
n-3 Fatty acids, which are abundant in ﬁsh and have been
associated with a protective effect concerning oesophageal
cancer, can stimulate anti-inﬂammatory signalling molecules(42).
This, again, demonstrates the biological plausibility of the
results shown.
We also observed a stronger association between the E-DII
and odds of oesophageal lesions among subjects with H. pylori
infection. As the statistical test for interaction was not signiﬁcant,
these results should be viewed with caution; however, the
possible reason for this observation could be that H. pylori
activates the NF-κB pathway, which is an important promoter of
carcinogenesis through the process of inﬂammation(5,43), and
this could be accelerated with a pro-inﬂammatory diet, as
indicated by increasing DII scores.
It is clear that analyses should be controlled for total energy
intake. However, such control requires careful consideration.
This is because there are two countervailing effects between
energy and nutrient intake. The ﬁrst is the tendency to eat more
of all nutrients as one increases energy intake; this results in a
positive correlation between energy intake and nutrient intake.
The other is what may be termed the ‘healthy eater’ effect
(i.e. due to the intention of careful, health-conscious people to
choose nutrient-dense, energy-sparse foods – in preference to
energy-dense, nutrient-sparse foods). Of course, its opposite is
the ‘unhealthy eater’ effect (i.e. showing a preference for
energy-dense, nutrient-sparse foods). Both of these types
of eaters produce results that show negative correlations
between DII scores and total energy intake. In previous
research we have observed that there is considerable variability
in how these eating behaviours are distributed across different
populations. The consequence is that there is variability in
results based on whether or not we control for energy, as well
as the method of control.
Regarding the speciﬁc method of control, the multivariate
nutrient density model is similar to, but not mathematically
equivalent to, the residual method of energy adjustment. Con-
sequently, results from the two methods are usually highly
correlated. In the multivariate nutrient density model, the
coefﬁcient has a substitution interpretation but is in units of
the percentage of energy from the nutrient. It can therefore be
directly translated into public health recommendations that are
expressed in these units. Because of the long-standing use of
nutrient densities by nutritionists and the application of nutrient
densities in public health recommendations, the multivariate
nutrient density model appears to deserve more widespread
use(44). We have additionally adjusted for energy intake
as recommended by Willett et al.(44) under the multivariate
nutrient density model.
There are several strengths of our population-based
case–control study, including the ability to study the DII in
Table 4. Dietary inflammatory index density and risk of reflux oesophagitis, Barrett’s oesophagus and oesophageal adenocarcinoma, stratified by
Helicobacter pylori status, Factors influencing the Barrett’s Adenocarcinoma Relationship study
(Odds ratios and 95% confidence intervals)
H. pylori negative H. pylori positive
Adjusted* Adjusted*
Controls/cases OR 95% CI Controls/cases OR 95% CI Pfor interaction
Reflux oesophagitis†
E-DII
<−0·12 9/15 1·00 30/19 1·00
−0·12−<1·91 16/51 1·35 0·42, 4·30 22/30 1·72 0·67, 4·39
≥1·91 16/59 1·58 0·49, 5·08 24/43 2·35 0·92, 6·01
Pfor trend 0·45 0·07 0·85
Barrett’s oesophagus
E-DII
<0·34 26/23 1·00 57/21 1·00
0·34−<1·98 43/41 1·01 0·47, 2·21 41/33 2·48 1·18, 5·23
≥1·98 34/40 1·25 0·55, 2·81 47/52 2·74 1·32, 5·65
Pfor trend 0·57 0·008 0·21
Oesophageal adenocarcinoma
E-DII
<0·34 26/19 1·00 57/21 1·00
0·34−<1·98 43/32 0·97 0·40, 2·31 41/35 2·45 1·15, 5·22
≥1·98 34/55 2·26 0·94, 5·41 47/46 2·38 1·15, 4·91
Pfor trend 0·04 0·03 0·13
DII, dietary inflammatory index.
* Adjusted for age (years), sex, energy intake, smoking status (current/previous/never), BMI 5 years before interview, education (years), occupation (manual/non-manual), alcohol
(g/d), regular non-steroidal inflammatory drug use (ever/never), and location (Northern Ireland/Republic of Ireland).
† Analysis limited to Northern Ireland controls only.
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relation to early inﬂammatory disease through to pre-malignant
and malignant lesions of the oesophagus. We also were able to
account for several potential confounders, most notably
H. pylori infection. Despite its strengths, we acknowledge that
the study has several limitations. First, it was necessary to
enquire about habitual dietary intakes 5 years before interview
in order to overcome reverse causation bias from the presence
of disease. This will have incurred the potential for recall
bias in our dietary assessment. In addition response rates of
population-based controls were considerably lower than that
of patient groups. However, previous comparisons with
national dietary surveys in Ireland suggest that dietary habits of
our controls are representative of the general population(45). A
further limitation of our study is that we were able to derive DII
from only twenty-ﬁve of the potential forty-ﬁve food and
nutrient items that can be used to compute this index. However,
other published studies also derive DII scores from a sub-
optimal number of items, and the ability to still detect signiﬁcant
associations suggests that this has only led to a potential
underestimate of the association between E-DII scores and
oesophageal lesion risk. However, some of the missing food
parameters such as saffron, ginger and turmeric are consumed
infrequently in this population; so, non-availability of these
parameters may not have exerted a major impact. Further to this
issue of calculating DII from fewer food parameters, we have
previously demonstrated in the Seasonal Variation of Blood
Cholesterol Study that DII scores calculated from forty-four food
parameters using the 24-h recalls and DII scores calculated from
twenty-seven food parameters using 7-d dietary recall resulted
in the same OR, where CRP (>3mg/l) was the study out-
come(11). Reviewing all previous publications on the DII, on
average twenty-seven food parameters can be derived from a
structured dietary assessment tool such as an FFQ to calculate
the DII, and the range is between nineteen and thirty-four
depending on the detail provided by the FFQ, the nature of the
nutrient database and whether ﬂavonoids were calculated.
In conclusion, our study suggests that subjects with OAC and
BE (and to a lesser extent RE) were more likely to have a
pro-inﬂammatory diet, as shown by higher DII scores.
However, this ﬁnding requires replication in other studies,
including prospective cohorts. This may require large consortia
efforts to achieve the sample sizes needed to study this rarer
cancer site.
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